Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
15
|
pubmed:dateCreated |
1996-6-3
|
pubmed:abstractText |
The mechanism of the antinociceptive effect of buprenorphine was assessed by administering selective mu-, mu1--, delta- and kappa-opioid receptor antagonists in mice. Intraperitoneal administration of buprenorphine, at doses of 0.3 to 3 mg/kg, produced dose-dependent antinociception in the tail-flick test. The antinociceptive activity of buprenorphine did not result from the activation of kappa- or delta-opioid receptors, since treatment with either nor-binaltorphimine, a selective kappa-opioid receptor antagonist, or naltrindole, a selective delta-opioid receptor antagonist, was completely ineffective in blocking buprenorphine-induced antinociception. However, the antinociceptive effect of buprenorphine was significantly antagonized by beta-funaltrexamine, a selective mu-opioid receptor antagonist. Moreover, selective mu1-opioid receptor antagonist, naloxonazine and naltrexonazine, also significantly antagonized the antinociceptive effect of buprenorphine. Co-administration of kappa- and delta-opioid receptor antagonist with the mu-opioid receptor antagonists had no significant effect on the antagonistic profiles of the mu-opioid receptor antagonists on the antinociceptive effect of buprenorphine. These results suggest that buprenorphine acts selectively at mu1-opioid receptors to induce antinociceptive effects in mice.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Analgesics, Opioid,
http://linkedlifedata.com/resource/pubmed/chemical/Antitussive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Buprenorphine,
http://linkedlifedata.com/resource/pubmed/chemical/Capsaicin,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Opioid
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0024-3205
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
3
|
pubmed:volume |
56
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
PL285-90
|
pubmed:dateRevised |
2003-11-14
|
pubmed:meshHeading |
pubmed-meshheading:8614238-Analgesics, Opioid,
pubmed-meshheading:8614238-Animals,
pubmed-meshheading:8614238-Antitussive Agents,
pubmed-meshheading:8614238-Buprenorphine,
pubmed-meshheading:8614238-Capsaicin,
pubmed-meshheading:8614238-Cough,
pubmed-meshheading:8614238-Male,
pubmed-meshheading:8614238-Mice,
pubmed-meshheading:8614238-Mice, Inbred ICR,
pubmed-meshheading:8614238-Receptors, Opioid
|
pubmed:year |
1995
|
pubmed:articleTitle |
Buprenorphine exerts its antinociceptive activity via mu 1-opioid receptors.
|
pubmed:affiliation |
Department of Pharmacology, Faculty of Pharmaceutical Sciences, Hoshi University, Tokyo, Japan.
|
pubmed:publicationType |
Journal Article
|